{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:07:01Z","timestamp":1789524421981,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.vaccine.2020.07.068","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T13:36:58Z","timestamp":1596202618000},"page":"6075-6077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines"],"prefix":"10.1016","volume":"38","author":[{"given":"Rebecca","family":"Forman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-8255","authenticated-orcid":false,"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Mossialos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.07.068_b0005","unstructured":"World Health Organization. Draft landscape of COVID-19 candidate vaccines; 2020."},{"key":"10.1016\/j.vaccine.2020.07.068_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","author":"Folegatti","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2020.07.068_b0015","unstructured":"CEPI. CEPI gets \u20ac140 million funding boost from Germany while expanding coronavirus vaccine search. CEPI 2020. https:\/\/cepi.net\/news_cepi\/cepi-gets-e140-million-funding-boost-from-germany-while-expanding-coronavirus-vaccine-search\/ (accessed March 16, 2020)."},{"key":"10.1016\/j.vaccine.2020.07.068_b0020","article-title":"Bill Gates to help fund coronavirus-vaccine development","author":"Calfas","year":"2020","journal-title":"Wall Str J"},{"key":"10.1016\/j.vaccine.2020.07.068_b0025","unstructured":"CEPI. Netherlands and Switzerland join the search for COVID-19 vaccines. CEPI 2020. https:\/\/cepi.net\/news_cepi\/netherlands-and-switzerland-join-the-search-for-covid-19-vaccines\/ [accessed April 25, 2020]."},{"key":"10.1016\/j.vaccine.2020.07.068_b0030","article-title":"Is the US-China rivalry tangling a coronavirus vaccine with geopolitics?","author":"Rahn","year":"2020","journal-title":"Dtsch Welle"},{"key":"10.1016\/j.vaccine.2020.07.068_b0035","unstructured":"Togoh I. Health Secretary Alex Azar refuses to guarantee coronavirus vaccine would be affordable for all. Forbes; 2020."},{"key":"10.1016\/j.vaccine.2020.07.068_b0040","article-title":"Big drugmakers under pressure to share patents against coronavirus","author":"Mancini","year":"2020","journal-title":"Financ Times"},{"key":"10.1016\/j.vaccine.2020.07.068_b0045","unstructured":"More than 150 countries engaged in COVID-19 vaccine global access facility n.d. https:\/\/www.who.int\/news-room\/detail\/15-07-2020-more-than-150-countries-engaged-in-covid-19-vaccine-global-access-facility [accessed July 26, 2020]."},{"key":"10.1016\/j.vaccine.2020.07.068_b0050","unstructured":"Cernuschi T. Advance Market Commitment: The Pneumococcal Pilot; 2009."},{"key":"10.1016\/j.vaccine.2020.07.068_b0055","unstructured":"The Boston Consulting Group. The Advance Market Commitment Pilot for Pneumococcal Vaccines: Outcomes and Impact Evaluation; 2015."},{"key":"10.1016\/j.vaccine.2020.07.068_b0060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1744-8603-9-58","article-title":"Incentives for new antibiotics: The Options Market for Antibiotics (OMA) model","volume":"9","author":"Brogan","year":"2013","journal-title":"Global Health"},{"key":"10.1016\/j.vaccine.2020.07.068_b0065","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.socscimed.2016.01.005","article-title":"Systems, not pills: the options market for antibiotics seeks to rejuvenate the antibiotic pipeline","volume":"151","author":"Brogan","year":"2016","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.vaccine.2020.07.068_b0070","article-title":"Germany confirms that Trump tried to buy firm working on coronavirus vaccine","author":"Hernandez-Morales","year":"2020","journal-title":"Politico"},{"key":"10.1016\/j.vaccine.2020.07.068_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057755","article-title":"Risk in vaccine research and development quantified","volume":"8","author":"Pronker","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.07.068_b0080","unstructured":"Coronavirus: Germany tries to stop US luring away firm seeking vaccine. CNBC; 2020."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20310124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20310124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:46:02Z","timestamp":1759401962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20310124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":16,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0264410X20310124"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.068","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}